Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
暂无分享,去创建一个
Bernhard Hemmer | Jeffrey L. Bennett | Hans-Peter Hartung | H. Hartung | B. Hemmer | J. Bennett | O. Stuve | B. Kieseier | Olaf Stuve | Bernd Kieseier | Amer Awad | Amer M. Awad | J. Bennett
[1] T. J. Murray. Multiple Sclerosis: The History of a Disease , 2004 .
[2] T. Brücke,et al. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.
[3] D. Keren. Optimizing detection of oligoclonal bands in cerebrospinal fluid by use of isoelectric focusing with IgG immunoblotting. , 2003, American journal of clinical pathology.
[4] K. Nékám,et al. Concentration of Soluble Adhesion Molecules (sVCAM-1, sICAM-1 and sL-Selectin) in the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis and Systemic Lupus erythematosus with Central Nervous Involvement , 2001, Neuroimmunomodulation.
[5] J. Losy,et al. Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients. , 2001, Folia neuropathologica.
[6] J. Correale,et al. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS , 2003, Journal of Neuroimmunology.
[7] H. Reiber,et al. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. , 1987, Clinica chimica acta; international journal of clinical chemistry.
[8] A. Minagar,et al. Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study , 2005, Journal of Neuroinflammation.
[9] A. Rovira,et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.
[10] D. Miller,et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.
[11] Michael J. Ramsbottom,et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.
[12] W. Tourtellotte,et al. Schemes to eradicate the multiple sclerosis central nervous system immune reaction , 1976, Neurology.
[13] D. Freedman,et al. The cerebrospinal fluid in multiple sclerosis. , 1934, Research publications - Association for Research in Nervous and Mental Disease.
[14] H. Tumani,et al. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.
[15] D. Hafler,et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid , 2009, Annals of neurology.
[16] W. Tourtellotte,et al. Immunoglobulin heavy chain associated protein in multiple sclerosis cerebrospinal fluid. , 1986, Molecular immunology.
[17] C. Granger,et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 , 1999, Journal of Neuroimmunology.
[18] M. Reindl,et al. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[19] B. Weinshenker,et al. Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index. , 2003, American journal of clinical pathology.
[20] H. Reiber. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. , 1995, Clinical chemistry.
[21] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[22] L. Villar,et al. Multiple sclerosis patients with anti‐lipid oligoclonal IgM show early favourable response to immunomodulatory treatment , 2009, European journal of neurology.
[23] E. Kabat,et al. AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. , 1942, The Journal of clinical investigation.
[24] E. Bock,et al. N-CAM in cerebrospinal fluid: a marker of synaptic remodelling after acute phases of multiple sclerosis? , 1987, Italian journal of neurological sciences.
[25] N. Gilhus,et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force , 2006, European journal of neurology.
[26] S. Takahashi,et al. Hashimoto encephalopathy: etiologic considerations. , 1994, Pediatric neurology.
[27] Z. Stelmasiak,et al. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients , 2005, Journal of Neural Transmission.
[28] C. Polman,et al. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients , 2003, Neuroscience Letters.
[29] M. Sharief,et al. Significance of CSF immunoglobulins in monitoring neurologic disease activity in Behçet's disease , 1991, Neurology.
[30] K. Trinkaus,et al. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis , 2006, Neurology.
[31] E. İdiman,et al. Intrathecal sICAM-1 production in multiple sclerosis Correlation with triple dose Gd-DTPA MRI enhancement and IgG index , 2005, Journal of Neurology.
[32] G. Bernardi,et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[33] H. Reiber,et al. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis , 1998, Multiple sclerosis.
[34] E. Merelli,et al. A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.
[35] T. Marra. Multiple Sclerosis with Onset after Age 60 , 1984, Journal of the American Geriatrics Society.
[36] David H. Miller,et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. , 2007, The New England journal of medicine.
[37] E. Thompson,et al. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. , 1990, Brain : a journal of neurology.
[38] J. Hillert,et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.
[39] L. Wahlund,et al. Diagnostic use of cerebral and extracerebral oxysterols , 2004, Clinical chemistry and laboratory medicine.
[40] G. McDonnell,et al. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis , 1998, Journal of Neuroimmunology.
[41] I. Steiner,et al. Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions. , 2000, Archives of neurology.
[42] T. Rosenberg,et al. Leber's hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation , 1995, Acta neurologica Scandinavica.
[43] H. Hartung,et al. Cerebrospinal fluid biomarkers in multiple sclerosis , 2009, Neurobiology of Disease.
[44] Z. Sučić,et al. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. , 2002, Cytokine.
[45] Y Ben-Shlomo,et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[46] Helena Chmura Kraemer,et al. Evaluating Medical Tests: Objective and Quantitative Guidelines , 1992 .
[47] J. Masjuán,et al. Clinically isolated syndromes , 2006, Neurology.
[48] S. Cepok,et al. Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.
[49] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[50] M. Trojano,et al. Cerebrospinal Fluid Analysis in Multiple Sclerosis , 1996, Springer Milan.
[51] W. Poewe,et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. , 1999, Brain : a journal of neurology.
[52] L. Rosengren,et al. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit , 1995, Journal of the Neurological Sciences.
[53] C. R. Snyder,et al. Cerebrospinal fluid analysis in human immunodeficiency virus infection. , 1992, Annals of clinical and laboratory science.
[54] B. Tavolato,et al. Free light chains in the CSF in multiple sclerosis , 1987, Journal of Neurology.
[55] Y. Qin,et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. , 1998, The Journal of clinical investigation.
[56] K. Nékám,et al. Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis. , 2003, Acta microbiologica et immunologica Hungarica.
[57] A. Bar-Or,et al. Do myelin-directed antibodies predict multiple sclerosis? , 2003, The New England journal of medicine.
[58] J. Ernerudh,et al. Improved Formulae for the Judgement of Intrathecal Produced IgA and IgM in the Presence of Blood CSF Barrier Damage , 1993, Annals of clinical biochemistry.
[59] D. Lütjohann,et al. Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.C400005-JLR200 , 2005, Journal of Lipid Research.
[60] V. Leoni. Oxysterols as markers of neurological disease – a review , 2009, Scandinavian journal of clinical and laboratory investigation.
[61] D. Gilden,et al. Comparative Analysis of the CD19+ and CD138+ Cell Antibody Repertoires in the Cerebrospinal Fluid of Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.
[62] G. Aimard,et al. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[63] E. Thompson,et al. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis , 1991, Annals of neurology.
[64] D. Hafler,et al. Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein1 , 2005, The Journal of Immunology.
[65] J. Bennett,et al. B‐lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid , 2004, Annals of neurology.
[66] A. Vighetto,et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. , 2001, Archives of neurology.
[67] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[68] M. Filippi,et al. Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients , 1993, Journal of Neuroimmunology.
[69] P. Rieckmann,et al. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis , 1998, Multiple sclerosis.
[70] N. Yanagisawa,et al. Increased levels of soluble vascular cell adhesion molecule-1 ( VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy , 1995, Journal of Neuroimmunology.
[71] M. Hennerici,et al. Vascular cell adhesion molecule — a new approach to detect endothelial cell activation in MS and encephalitis in vivo , 1996, Acta neurologica Scandinavica.
[72] J. Bennett,et al. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis , 2009, Journal of Neuroimmunology.
[73] F. Deisenhammer,et al. Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelinating diseases , 2005, European journal of neurology.
[74] S. Sorbi,et al. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis , 2009, Multiple sclerosis.
[75] C. Granger,et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1999, Journal of neuroimmunology.
[76] J. Frederiksen,et al. The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae , 1996 .
[77] J. Bennett,et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome , 2008, Journal of Neuroimmunology.
[78] D. Gilden,et al. Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.
[79] E. Thompson,et al. Short communication CNS tumours: oligoclonal immunoglobulin D in cerebrospinal fluid and serum , 1999, Acta neurologica Scandinavica.
[80] J. Fischer,et al. Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains , 1995, Multiple sclerosis.
[81] C. Polman,et al. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis , 2005, The Lancet Neurology.
[82] A. Bar-Or,et al. Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .
[83] F. Barkhof,et al. Multiple sclerosis , 2003, Neurology.
[84] E. Byrne,et al. Symptomatic female heterozygotes for adrenoleukodystrophy: A report of two unrelated cases and review of the literature , 1996, Journal of clinical neuroscience.
[85] J. Gómez-Rial,et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis , 2009, Journal of Neuroimmunology.
[86] R. Shenkar,et al. Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. , 2007, Journal of neurosurgery.
[87] N. Scolding,et al. Neurosarcoidosis: a study of 30 new cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[88] S. Poser,et al. Age at onset, initial symptomatology and the course of multiple sclerosis , 1982, Acta neurologica Scandinavica.
[89] U. Bogdahn,et al. Borrelia burgdorferi—specific and autoreactive T‐cell lines from cerebrospinal fluid in lyme radiculomyelitis , 1988, Annals of neurology.
[90] S. Hawkins,et al. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 , 1996, Journal of Neuroimmunology.
[91] C. Laurell,et al. Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. , 1974, Clinical chemistry.
[92] Roland Martin,et al. Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis☆ , 1989, Journal of Neuroimmunology.
[93] Z. Sfaello,et al. Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system , 1970, Neurology.
[94] J. Ernerudh,et al. Comparison of Seven Formulae and Isoelectrofocusing for Determination of Intrathecally Produced IgG in Neurological Diseases , 1992, Annals of clinical biochemistry.
[95] I. Catz,et al. A myelin basic protein antibody cascade in purified IgG from cerebrospinal fluid of multiple sclerosis patients , 1990, Journal of the Neurological Sciences.
[96] H. Ulmer,et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.
[97] A. Carpentier,et al. Cerebrospinal fluid study in paraneoplastic syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[98] J. Bednářová. Cerebrospinal-fluid profile in neuroborreliosis and its diagnostic significance , 2008, Folia Microbiologica.
[99] K. Nékám,et al. Soluble L‐selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus , 2000, Acta neurologica Scandinavica.
[100] M. Freedman,et al. The prognostic significance of cerebrospinal fluid in multiple sclerosis , 2009, Journal of the Neurological Sciences.
[101] H. Link,et al. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.
[102] A. Salmaggi,et al. Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients , 1998, Journal of Neuroimmunology.
[103] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[104] K. Nékám,et al. A study of increased levels of soluble vascular cell adhesion molecule‐1 (SVCAM‐1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus , 1999, Acta neurologica Scandinavica.
[105] G. McDonnell,et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. , 2000, Acta neurologica Scandinavica.
[106] F. Bouwman,et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.
[107] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[108] L. Fratiglioni,et al. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis , 1991, Acta neurologica Scandinavica.
[109] M. Spiegel-Adolf,et al. Cerebrospinal fluid. , 1965, Progress in neurology and psychiatry.
[110] H. Merritt,et al. The cerebrospinal fluid , 1938 .
[111] S. West,et al. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. , 1995, The American journal of medicine.
[112] P. Forsberg,et al. An improved formula for the judgement of intrathecally produced IgG in the presence of blood brain barrier damage. , 1989, Clinica chimica acta; international journal of clinical chemistry.
[113] P. Narayana,et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.
[114] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[115] C. Lombard,et al. Diagnostic et surveillance biologique de six neurosyphilis : apport de l’étude du liquide céphalorachidien , 2003 .
[116] P. Vermersch,et al. Neurologic Manifestations in Primary Sjögren Syndrome: A Study of 82 Patients , 2004, Medicine.
[117] P. Mehta,et al. Absence of oligoclonal IgA in CSF and serum of multiple sclerosis patients , 1984, Journal of Neuroimmunology.